Le Lézard
Classified in: Health, Science and technology
Subjects: PER, TRI

Imagion Biosystems Appoints Dr Farideh Bischoff as Vice President of Clinical Research


MELBOURNE, Australia, Feb. 21, 2018 /PRNewswire/ -- Imagion Biosystems Limited (ASX:IBX) (Imagion or the Company), a company dedicated to improving healthcare through earlier detection of cancer, announces the appointment of Farideh Bischoff, PhD, as Vice President of Clinical Research. Dr Bischoff will lead the clinical program for the company's MagSensetm cancer detection technology, working to achieve regulatory approval as a diagnostic device for the early detection of malignant tumor cells.

Dr Bischoff adds a wealth of relevant experience in oncology product commercialisation to the leadership team at Imagion Biosystems. Her accomplishments include scientific development, regulatory submission and successful commercialisation of molecular diagnostics for Biocept. She has led numerous productive collaborative studies, including the NIFTY NIH Fetal Cell Study, composed of individuals from academic, pharmaceutical and biotech organisations.

She is widely recognised in the fields of rare cancer cell detection, molecular cytogenetics, diagnostic assay development and validation. Dr Bischoff holds a PhD from the University of Texas Graduate School of Biological Sciences, Houston. Her doctoral thesis led to the discovery of the p53 tumor suppressor gene and the emergence of a productive new avenue of global cancer research.

"We are very pleased to welcome Dr Bischoff to Imagion Biosystems as we progress toward first-in-human clinical studies," said Imagion Executive Chairman and CEO Bob Proulx.

"Dr Bischoff has the background and experience to help us move into the clinical setting, an area where she has worked for many years," he added.

"I'm excited to be joining Imagion Biosystems as the company advances MagSensetm technology to the first-in-human clinical trial," said Dr Bischoff.

"The role at Imagion enables me to follow my passion for improving the lives of cancer patients. There is a large unmet medical need for earlier detection of malignant tumors."

About Imagion Biosystems
Imagion Biosystems is developing the MagSensetm bioimaging system to detect cancer and other diseases earlier and with higher specificity than is currently possible. With MagSenseTM technology, the company has the potential to optimize patient care and reduce mortality rates across various cancer indications. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

 

SOURCE Imagion Biosystems


These press releases may also interest you

at 05:26
Alfa Laval's annual and sustainability report for 2023 has today been published and can be downloaded from the Group's website.  It is also attached to this press release. This is Alfa Laval   The ability to make the most of what we have is more...

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:05
Sovos, the always-on compliance company, today announced a joint business relationship with the Belgian PwC Firm PwC Business Advisory Services bv/srl (hereinafter: "PwC"), leveraging the companies' complementary tax and advisory service expertise...

at 05:05
The Ministry of Education and Science, along with Palantir , a leading provider of AI systems, have signed an agreement. The main goal is to facilitate qualitative transformations in the field of education and ensure the maximum number of children...

at 05:05
Building upon its recent success in revamping its indices product offering, leading CFD broker Vantage Markets ("Vantage") is thrilled to announce the introduction of enhanced website features and app enhancements, further solidifying its position as...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...



News published on and distributed by: